In patients with poor ovarian response, increasing the FSH dose during ovarian stimulation may increase the number of oocytes retrieved and reduce the risk of cycle cancellation due to insufficient response; conversely, in patients predicted to have a hyper-response to FSH, decreasing the FSH dose may reduce the risk of OHSS and related risk for cycle cancellation. Here, BRD2 is linked to ovarian hyperstimulation syndrome.